Neuromyelitis Optica Spectrum Disorder Clinical Trials

13 recruiting

Neuromyelitis Optica Spectrum Disorder Trials at a Glance

28 actively recruiting trials for neuromyelitis optica spectrum disorder are listed on ClinicalTrialsFinder across 6 cities in 21 countries. The largest study group is Phase 2 with 6 trials, with the heaviest enrollment activity in Wuhan, Tianjin, and Beijing. Lead sponsors running neuromyelitis optica spectrum disorder studies include Tongji Hospital, Alexion Pharmaceuticals, Inc., and Amgen.

Browse neuromyelitis optica spectrum disorder trials by phase

Treatments under study

About Neuromyelitis Optica Spectrum Disorder Clinical Trials

Looking for clinical trials for Neuromyelitis Optica Spectrum Disorder? There are currently 13 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Neuromyelitis Optica Spectrum Disorder trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Neuromyelitis Optica Spectrum Disorder clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 28 trials

Recruiting
Phase 3

A Study To Evaluate Pharmacokinetics, Efficacy, Safety, Tolerability, And Pharmacodynamics Of Satralizumab In Pediatric Patients With Aquaporin-4 Antibody Positive Neuromyelitis Optica Spectrum Disorder (NMOSD)

Neuromyelitis Optica Spectrum DisorderNMOSD
Hoffmann-La Roche8 enrolled13 locationsNCT05199688
Recruiting
Phase 1

Safety and Pharmacodynamics of QH103 Cell Injection in the Treatment of Patients With Relapsed/Refractory Antibody-Mediated Neurological Autoimmune Diseases.

Neuromyelitis Optica Spectrum Disorder (NMOSD)Multiple Sclerosis (MS)Myasthenia Gravis (MG)+3 more
Tongji Hospital6 enrolled1 locationNCT07526493
Recruiting
Phase 4

Therapy in the Acute Phase of NMOSD: A Multicenter Prospective Real-World Study

Neuromyelitis Optica Spectrum Disorder Attack
Chinese PLA General Hospital200 enrolled1 locationNCT07410039
Recruiting
Phase 4

Modified Zipper Therapy for AQP4-IgG Positive Neuromyelitis Optica Spectrum Disorder

Neuromyelitis Optica Spectrum Disorders (NMOSD)
Tianjin Medical University General Hospital198 enrolled1 locationNCT07420296
Recruiting

Registry of Patients With AQP4+ NMOSD Treated With Alexion C5 Inhibitor Therapies

Neuromyelitis Optica Spectrum DisorderNMOSDAQP4+ NMOSD
Alexion Pharmaceuticals, Inc.122 enrolled33 locationsNCT05966467
Recruiting
Phase 1Phase 2

Ofatumumab in AQP4-IgG Seropositive NMOSD

Neuromyelitis Optica Spectrum Disorder
Tang-Du Hospital5 enrolled1 locationNCT05504694
Recruiting

Observational Safety Study in Women With Neuromyelitis Optica Spectrum Disorder (NMOSD) Exposed to UPLIZNA® During Pregnancy

Pregnancy RelatedNeuromyelitis Optica Spectrum Disorder
Amgen60 enrolled1 locationNCT05909761
Recruiting
Phase 1

The Safety and Efficacy of NouvSoma001 in Neuromyelitis Optica Spectrum Disorders

Neuromyelitis Optica Spectrum Disorders
Tongji Hospital69 enrolled1 locationNCT06620809
Recruiting

French Registry for Monitoring Pregnancies for Multiple Sclerosis

Sclerosis, MultipleNeuromyelitis Optica Spectrum DisorderMyelin Oligodendrocyte Glycoprotein (MOG)-Antibody Related Disorders+1 more
Hospices Civils de Lyon1,500 enrolled48 locationsNCT03900221
Recruiting
Early Phase 1

Universal Chimeric Antigen Receptor T-Cell (UCAR T-cell) Therapy Targeting CD19/B Cell Maturation Antigen (CD19/BCMA) in Patients With r/r Neurological Autoimmune Diseases

Myasthenia GravisAutoimmune EncephalitisMultiple Sclerosis+2 more
Tianjin Huanhu Hospital12 enrolled1 locationNCT06939166
Recruiting
Phase 2

Study of Inebilizumab in Pediatric Subjects With Neuromyelitis Optica Spectrum Disorder

Neuromyelitis Optica Spectrum Disorder
Amgen15 enrolled19 locationsNCT05549258
Recruiting
Phase 2Phase 3

Efficacy and Safety Study of Ravulizumab IV in Pediatric Participants With NMOSD

Neuromyelitis Optica Spectrum Disorder
Alexion Pharmaceuticals, Inc.12 enrolled21 locationsNCT05346354
Recruiting

Integrating Metabolism, Connectivity, and Mesoscale Imaging at Ultra-high Field to Decipher Mechanisms of Resilience and Neurodegeneration in Neurological Diseases and Healthy Aging

Multiple SclerosisAlzheimer DiseaseParkinson Disease+2 more
Assistance Publique Hopitaux De Marseille700 enrolled1 locationNCT07202494
Recruiting
Phase 2

Eculizumab For the Acute Attack of Neuromyelitis Optica Spectrum Disorder

Neuromyelitis Optica Spectrum Disorder Attack
Tianjin Medical University General Hospital110 enrolled1 locationNCT07184840
Recruiting
Phase 1

A Study of C-CAR168 in the Treatment of Autoimmune Diseases Refractory to Standard Therapy

Myasthenia GravisSystemic Lupus Erythematosus (SLE)Multiple Sclerosis (MS)+3 more
RenJi Hospital30 enrolled1 locationNCT06249438
Recruiting
Not Applicable

Protein A immuNoaDsorption for the Treatment of Acute Episodes of Neuromyelitis Optica Spectrum Disorder

Neuromyelitis Optica Spectrum Disorders
Third Affiliated Hospital, Sun Yat-Sen University144 enrolled1 locationNCT06763848
Recruiting
Not Applicable

Impact of a Structured Wellness Behavioral Intervention on Quality of Life in NMOSD

Neuromyelitis Optica Spectrum Disorder (NMOSD)
Icahn School of Medicine at Mount Sinai20 enrolled1 locationNCT06780709
Recruiting
Not Applicable

Frequency of FCGR3A Gene Polymorphisms in Patients With Neuromyelitis Optica Spectrum Disorders, Anti-oligodendrocyte Myelin Protein Antibody Disease, and Multiple Sclerosis.

Multiple SclerosisNeuromyelitis Optica Spectrum DisordersMOGAD
Fondazione Policlinico Universitario Agostino Gemelli IRCCS50 enrolled1 locationNCT06865274
Recruiting
Phase 2Phase 3

A Clinical Study of B001 Injection in the Treatment of Neuromyelitis Optica Spectrum Disorders(NMOSD)

Neuromyelitis Optica Spectrum Disorders
Shanghai Jiaolian Drug Research and Development Co., Ltd132 enrolled51 locationsNCT06413654
Recruiting

Swiss Pediatric Inflammatory Brain Disease Registry (Swiss-Ped-IBrainD)

Multiple SclerosisOptic NeuritisTransverse Myelitis+15 more
University of Bern500 enrolled13 locationsNCT05017142